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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanWe report our experience with a preterm infant with severe hemolytic jaundice who required
exchange transfusion just after birth. The patient was negative for alloimmune hemolysis as a
result of maternalefetal blood type incompatibility, and tests for inherited defects in erythro-
cyte metabolism, membrane function, and hemoglobin synthesis were normal. We also per-
formed a bone marrow examination, but could not identify the cause of hemolysis. The
patient had several other complications, including porencephaly, epilepsy, elevated serum
levels of creatine kinase, and persistent microscopic hematuria. Later, we detected a genetic
mutation in COL4A1, which was recently found to be associated with hemolytic anemia. We
therefore believe that all of the patient’s clinical features, including hemolytic anemia, were
due to the mutation in COL4A1. Genetic testing for COL4A1 mutations is recommended in ne-
onates who exhibit hemolytic disease of unknown etiology, especially when other complica-
tions compatible with COL4A1-related disorders are present.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Hemolysis is the most important cause of severe hyper-
bilirubinemia during the early neonatal period. Withoutof Pediatrics, Kitano Hospital, Taz
ahoo.co.jp (S. Tomotaki).
014.04.001
Pediatric Association. Published bappropriate treatment, hyperbilirubinemia can develop into
kernicterus, particularly in preterm infants. The major
causes of neonatal hemolytic jaundice are alloimmunization
(maternalefetal blood type incompatibility) and congenitaluke Kofukai, Medical Research Institute, 2-4-20 Ohgimachi, Kita-ku,
y Elsevier Taiwan LLC. All rights reserved.
Severe hemolytic jaundice in a neonate 523disorders of red blood cells, such as hereditary spherocytosis
and glucose-6-phosphate dehydrogenase deficiency.
Here, we present a preterm small-for-date infant
with severe hyperbilirubinemia and anemia who required
exchange transfusion just after birth. The patient had
several other complications, including imaging abnormal-
ities in the central nervous system, epilepsy, elevated
serum levels of creatine kinase, and persistent microscopic
hematuria. All of these clinical features were attributed to
a novel mutation in COL4A1, which was detected when the
patient reached 2 years of age.2. Case Report
A male infant was delivered at 34 weeks of gestation by
elective cesarean section in response to fetal growth ar-
rest, and had Apgar scores of 8 and 9 at 1 minute and 5
minutes, respectively. The patient was the first son of un-
related healthy parents. His family members had no med-
ical history of hemolytic disease. At birth, he was
symmetrically growth retarded with a weight of 1422 g
[e2.4 standard deviation (SD)], length of 40.0 cm (1.7
SD), and head circumference of 27.6 cm (1.9 SD). On
admission, the neonate’s total bilirubin level was high
(4.7 mg/dL), and he was started on intensive phototherapy
immediately after birth. However, 12 hours later, his total
bilirubin level rose further to 10.5 mg/dL and the hemo-
globin level decreased from 11.8 g/dL to 9.6 g/dL. There-
fore, we performed exchange transfusion on Day 0 and Day
1. Both the patient’s and mother’s blood were type B
(RhDþ), and yielded negative results with the direct
Coombs test. Reticulocyte levels were elevated by 89&,
carbon monoxideehemoglobin concentration was elevated
by 3.8%, and a peripheral blood smear showed moderate
anisocytosis and polychromasia. There was no massive
hemorrhage in the cerebral ventricles, liver, adrenal
glands, or other intraperitoneal organs. After exchange
transfusion, hyperbilirubinemia and hemolytic anemia
improved. Although recombinant erythropoietin was
administered from Day 2, anemia progressively worsened
(hemoglobin level decreased from 13.2 g/dL to 5.1 g/dL in
20 days), and the patient required a red blood cell trans-
fusion on Day 29 (Figure 1). Inherited defects of erythrocyteFigure 1 Clinical course. Exchange transfusion was performed on
on Day 29. Hyperbilirubinemia improved after exchange transfusion
Hb Z hemoglobin; t-Bil Z total bilirubin.metabolism (glucose-6-phosphate dehydrogenase defi-
ciency, pyruvate kinase deficiency, and other erythrocyte
enzyme defects) were not detected by genetic analysis.
Defects in membrane function (hereditary spherocytosis
and hereditary elliptocytosis) and hemoglobin synthesis
(sickle cell disease, thalassemia, and other hemoglobinop-
athies) were also not detected. A bone marrow specimen
on Day 52 showed erythroid hyperplasia, but no signs of
malignant disease. Tests for specific antibodies against
toxoplasmosis, rubella, cytomegalovirus, and herpes sim-
plex were negative, and no cytomegalovirus DNA was found
in the patient’s urine. Blood and urine cultures were
negative for viral pathogens. Chromosomal analysis
revealed a normal male karyotype. No abnormalities were
found in diagnostic tests for common inborn errors of
metabolism. We were unable to identify the cause of he-
molysis in the neonatal period. His anemia improved after
red cell transfusion, and there was no recurrence of anemia
thereafter. The patient was discharged at age 2 months.
Cranial magnetic resonance imaging on Day 39 as a
matter of routine for very low birth weight infants revealed
dilated lateral ventricles with irregular walls (por-
encephaly; Figure 2). During follow-up, hemiplegia with
mild motor and mental retardation, strabismus, and epi-
lepsy were observed. Occasionally, high serum creatine
kinase levels (500e2,000 IU/L) and persistent microscopic
hematuria were noticed. Later, genetic analysis of COL4A1
revealed a heterozygous mutation in the COL4A1 gene:
c.3245G>A (p.Gly1082Glu).
Informed consent to report this case was obtained orally
from the neonate’s parents.3. Discussion
Here, we present the case of a preterm small-for-date in-
fant who exhibited severe hyperbilirubinemia and pro-
longed anemia. The clinical course and laboratory data
strongly suggested hemolytic disease. Hemolytic disease in
newborns can have multiple causes, such as alloimmune
hemolytic disease and inherited defects in erythrocyte
metabolism, membrane function, or hemoglobin synthesis
(Table 1).1,2 Despite our systematic approach, we could not
identify the cause of the patient’s hemolysis during theDay 0 and Day 1 and red blood cell transfusion was performed
. Anemia improved after red cell transfusion and did not recur.
Figure 2 Cranial magnetic resonance imaging on Day 39.
T1-weighted imaging shows enlarged lateral ventricles with
irregular walls.
524 S. Tomotaki et alneonatal period. There was concern that the patient’s
anemia would worsen with viral infections, especially
human parvovirus B19 infection; however, despite several
infections, anemia did not recur until later. The transient
nature of his anemia could not be explained.Table 1 Causes of hyperbilirubinemia in neonates.1,2
Hemolysis
Alloimmune hemolytic disease (maternalefetal blood
type incompatibility)
ABO incompatibility
Rh isoimmunization
Minor blood group incompatibility
Inherited defects of erythrocyte metabolism
Glucose-6-phosphate dehydrogenase deficiency
Pyruvate kinase deficiency
Pyrimidine 5’-nucleotidase deficiency
Glucose phosphate isomerase deficiency
Phosphofructokinase deficiency
Phosphoglycerate kinase deficiency
Aldolase deficiency
Hexokinase deficiency
Enolase deficiency
Adenylate kinase deficiency
Adenosine deaminase overproductive disease
Inherited defects of erythrocyte membrane function
Hereditary spherocytosis
Hereditary elliptocytosis
Stomatocytosis
Pyknocytosis
Inherited defects of hemoglobin synthesis
Sickle cell disease
Thalassemia
HemoglobinopathyRecently, we reported the clinical features of 15 Japanese
patients with COL4A1 mutations. One-third of them suffered
from hemolytic anemia that spontaneously resolved within
several months.3 Other clinical features of COL4A1-related
disorders include intracerebral hemorrhage, ischemic stroke,
porencephaly detected by neuroimaging, infantile hemiple-
gia, seizures, intellectual disability, hematuria, muscle
cramps with elevated creatine kinase levels, and ophthal-
mologic disorders.3e6 Therefore, the clinical findings of this
case, such as persistent microhematuria, elevated serum
levels of creatine kinase, and porencephaly with central
nervous system-related symptoms, in addition to hemolytic
anemia in the neonatal period, were consistent with the
presence of a COL4A1mutation.
Type IV collagens are basement membrane proteins that
are expressed in all tissues, including the vasculature, and can
dynamically influence a broad range of biological processes.7
COL4A1 (a1 chain) andCOL4A2 (a2 chain) forma triple-helical
structure by combining as heterotrimers with a 2:1 stoichi-
ometry (a1a1a2).1 COL4A1 forms a sheet-like network found
beneath both the endothelium and the surrounding smooth
muscle cells, and has important roles in maintaining the
cohesiveness of basement membranes and in endothelial cell
function.8 COL4A1 contains domains consisting of glycine-X-Y
amino acid repeats, which are essential for the formation of
the triple-helical structure. In the present case, amutation in
theCOL4A1 gene (c.3245G>A) resulted in the substitutionof aNonhemolysis
Extravascular blood
Cephalhematoma
Pulmonary hemorrhage
Cerebral hemorrhage
Intra-abdominal hemorrhage
Prematurity including late-preterm gestation
Infections
Sepsis
Enhanced enterohepatic bilirubin circulation
Intestinal obstruction
Ileus, meconium plugging, cystic fibrosis
Swallowed blood
Breast milk feeding
Hormonal deficiency
Hypothyroidism
Hypopituitarism
Polycythemia
Twinetwin transfusion
Delayed cord clamping
Maternofetal transfusion
Infant of diabetic mother
Impaired hepatic bilirubin uptake
Patent ductus venosus
SLCO1B1 gene polymorphisms
Disorders of bilirubin conjugation e UGT1A1 gene variants
CriglereNajjar syndrome type I
CriglereNajjar syndrome type II
Gilbert disease
Severe hemolytic jaundice in a neonate 525glycine for a glutamic acid residue in one of the glycine-X-Y
repeats. Therefore, this mutation is likely to result in
disruption in the triple-helical structure of the protein and
cause several symptoms.
Here, we reported that a COL4A1 mutation can cause
hemolytic anemia. Van Agtmael et al9 revealed that red blood
cell number and hematocrit of COL4A1 mutant mice were
significantly lower than those of wild type mice (8.55  1012
RBC/L and 38% hematocrit vs. 9.50  1012 RBC/L and 45%
hematocrit). However, the mechanisms via which COL4A1
mutations lead to hemolysis are not yet known. One possi-
bility is that COL4A1 mutations result in structural or func-
tional changes to basement membranes, which can lead to
defective transmigration of red blood cells or their pro-
genitors, and the subsequent destruction of these cells. Prior
to being released into the peripheral blood, blood progenitor
cells, including CD34þ cells, transmigrate to the basement
membranes of the bone marrow vasculatures. In this process,
blood progenitor cells have to breach the basement mem-
branes by matrix-degrading enzymes capable of degrading
type IV collagen.10 Janowska-Wieczorek et al10 reported that
peripheral blood CD34þ cells, but not steady-state bone
marrow CD34þ cells, strongly express collagen type IV
degrading gelatinases, matrix metalloproteinases-2 (MMP-2),
and MMP-9. This suggests that type IV collagens can dynami-
cally influence the transmigration of blood progenitor cells.
We also speculate that fetal hemoglobin may be more
vulnerable to this damage than adult hemoglobin, which may
explain why hemolysis is transient in patients with the
COL4A1 mutation. Further studies are required to clarify the
role of COL4A1 mutations in hemolytic anemia.
In conclusion, we report a preterm small-for-date infant
who experienced severe hemolytic jaundice soon after
birth. Genetic testing for COL4A1 mutations is recom-
mended in neonates with hemolytic disease of unknown
cause, especially when other complications compatible
with COL4A1-related disorders are present.
Conflicts of interest
All contributing authors declare no conflicts of interest.Acknowledgments
We would like to thank Dr H. Saitsu for the genetic analysis.References
1. Christine AG, Sherin UD. Avery’s diseases of the newborn. 9th
ed. Philadelphia: Saunders; 2012. p. 1123e42.
2. Janet MR. Rennie and Roberton’s textbook of neonatology. 5th
ed. 2012. p. 672e92.
3. Yoneda Y, Haginoya K, Kato M, Osaka H, Yokochi K, Arai H,
et al. Phenotypic spectrum of COL4A1 mutations: por-
encephaly to schizencephaly. Ann Neurol 2013;73:48e57.
4. Kelemen-Valkony I, Kiss M, Csiha J, Kiss A, Bircher U,
Szidonya J, et al. Drosophila basement membrane collagen
col4a1 mutations cause severe myopathy. Matrix Biol 2012;31:
29e37.
5. Plaisier E, Gribouval O, Alamowitch S, Mougenot B, Prost C,
Verpont MC, et al. COL4A1 mutations and hereditary angiop-
athy, nephropathy, aneurysms, and muscle cramps. N Engl J
Med 2007;357:2687e95.
6. Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K,
Massin P, et al. Role of COL4A1 in small-vessel disease and
hemorrhagic stroke. N Engl J Med 2006;354:1489e96.
7. Kuo DS, Labelle-Dumais C, Gould DB. COL4A1 and COL4A2
mutations and disease: insights into pathogenic mechanisms
and potential therapeutic targets. Hum Mol Genet 2012;21:
R97e110.
8. Vahedi K, Alamowitch S. Clinical spectrum of type IV collagen
(COL4A1) mutations: a novel genetic multisystem disease. Curr
Opin Neurol 2011;24:63e8.
9. Van Agtmael T, Bailey MA, Schlo¨tzer-Schrehardt U, Craigie E,
Jackson IJ, Brownstein DG, et al. Col4a1 mutation in mice
causes defects in vascular function and low blood pressure
associated with reduced red blood cell volume. Hum Mol Genet
2010;19:1119e28.
10. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML,
Montan˜o J, Chang H, et al. Growth factors and cytokines
upregulate gelatinase expression in bone marrow CD34(þ) cells
and their transmigration through reconstituted basement
membrane. Blood 1999;93:3379e90.
